3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Carcinoma, Hepatocellular
129
Carcinoma, Renal Cell
36
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Neoplasms
27
Cholangiocarcinoma
23
Endometrial Neoplasms
19
Liver Neoplasms
16
Melanoma
15
Thyroid Neoplasms
13
Stomach Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Biliary Tract Neoplasms
12
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Ovarian Neoplasms
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Small Cell Lung Carcinoma
5
Neuroendocrine Tumors
5
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Adenocarcinoma
4
Thyroid Cancer, Papillary
3
Solid Tumors
3
Interventions
pembrolizumab
7
Radiotherapy
3
Proton Therapy
3
Interleukin-2
3
Cyclophosphamide
3
spartalizumab
2
fludarabine
2
Rosuvastatin Calcium
2
Paclitaxel
2
Ipilimumab
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
Carboplatin
2
Blood Specimen Collection
2
toripalimab
1
tislelizumab
1
sotorasib
1
peposertib
1
pazopanib
1
patritumab deruxtecan
1
palbociclib
1
osimertinib
1
niraparib
1
neotil
1
necitumumab
1
mirdametinib
1
leronlimab
1
lenvatinib
1
atezolizumab
1
apatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumor, Adult
×
lenvatinib
×
Clear all
NCT06032845
2025-02-27
CASTLE-11
Fudan University
Phase 2
Recruiting
25 enrolled